🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being viewed as a "major milestone" in the effort against drug-resistant strains of the pathogen, according to scientists.

A Global Challenge

Gonorrhoea infections are increasing worldwide, with estimates suggesting more than 82 million instances annually. Particularly high rates are reported in the African continent and nations within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. Within England, cases have hit a historical peak, while rates across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely development in the reality of increasing worldwide cases, the spread of superbugs and the very limited therapeutic options at this time.”

Public health authorities are particularly alarmed about the increase in drug-resistant strains. The global health body has classified it as a "priority pathogen". Ongoing monitoring found that the effectiveness of key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Drugs Receive Authorization

Zoliflodacin, also known as a brand name, was cleared by the US Food and Drug Administration in recent days for treating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Experts believe that focused deployment of this new drug will help slow the spread of drug resistance.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, also received approval in the same week. This treatment, which is also used to treat urinary tract infections, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin emerged from a unique collaborative effort for medication research. The charitable organization GARDP worked alongside the pharmaceutical company its industry partner to develop it.

“This milestone signifies a major breakthrough in the treatment of superbug gonorrhoea, which previously has been outpacing antibiotic development.”

Testing Data and Global Access

As per results published in a prominent scientific publication, the new drug cured over nine in ten of genital gonorrhoea infections. This puts it on an similar efficacy with the current standard treatment, which combines an injection and a pill. The study enrolled nearly 1,000 patients from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, GARDP has the ability to register and commercialise the drug in a wide range of low-income and middle-income countries.

Doctors directly involved have voiced optimism. Having a single-dose, oral treatment such as this is described as a "revolutionary step" for gonorrhoea control. This is viewed as essential to alleviate the strain of the illness for patients and to stop the proliferation of highly drug-resistant gonorrhoea around the world.